CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CD70 CAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CD70 CAR-T overview

Gene-modified cell therapy is under development for the treatment of renal cell carcinoma, glioblastoma, B-cell non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, burkitt's lymphoma, mantle cell lymphoma, anaplastic large cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia and urothelial cancer. The therapy comprises of autologous T-cells that are genetically engineered to express chimeric antigen receptors (CARs) targeting cells expressing CD70 antigen (CD70). It is administered through parenteral and intravenous route.

UTC Therapeutics overview

UTC Therapeutics is a biotechnology company providing T cell based treatments for cancers and other diseases. UTC Therapeutics is headquartered in Shanghai, China.

For a complete picture of CD70 CAR-T’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.